Life Science News
Latest updates from the biotech and pharma world
Earnings roundup: Amgen vs. FDA, Pfizer’s defense and Merck’s $70B-in-sales plan
Amgen advances toward lupus redemption while gastric cancer candidate struggles
FDA seeks withdrawal of Amgen's Tavneos, company says it won't pull drug
Amgen quits Kyowa Kirin deal, returns rocatinlimab
Amgen gives up on its once-prized eczema drug
Amgen jilts Kyowa, exiting $400M autoimmune pact after running vast pivotal program
JPM26, Day 2: Amgen touts MariTide's showing in exploratory weight loss maintenance study
Amgen dances with Disco in $618M cancer target pact
Cancer biotech Disco lines up Amgen as first pharma partner
Amgen buys protein-degrading startup Dark Blue for up to $840M
Amgen stitches new acquisition worth up to $840M for UK biotech and its cancer programs
Amgen to acquire Dark Blue Therapeutics for up to $840M
FDA broadens label for Amgen's Uplizna as it enters rare disease competition
Amgen obesity marketing leader Chris Boulton takes reins at metabolic biotech Prolynx
Weight loss biotech Prolynx gets $70M, snags Amgen's obesity commercial leader as CEO
Amgen describes new GTPase KRAS mutant inhibitors
Biotechnology Market Therapeutic Innovations & Forecast Report 2025-2033 Featuring Lonza, Amgen, Syngenta, Biocon, Biogen, F. Hoffmann-La Roche, Novartis, Novo Nordisk A/S, Pfizer, and Seagen - ResearchAndMarkets.com - Business Wire
#Therapeutic Innovations#Forecast Report#Featuring Lonza#Novo Nordisk#Market Therapeutic
Cytiva Subsidiary Seeks to Quash Subpoena Issued in Amgen’s US Denosumab Litigation Against Accord & Intas - Pearce IP
#Subsidiary Seeks#Quash Subpoena#Subpoena Issued#Denosumab Litigation#Cytiva Subsidiary